Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 11, 2024HaematologicaOpen Access

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NPNoemí PuigInstituto de Investigación Biomédica de SalamancaCACristina AgullóUniversidad de SalamancaTCTeresa ContrerasComplejo Hospitalario de Salamanca

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Puig et al. (2024) studied this question.

synapsesocial.com/papers/68e609ceb6db64358759d6dahttps://doi.org/10.3324/haematol.2024.285742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials2022 · 62 citations
  2. 2New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells2007 · 588 citations
  3. 3Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024 · 22 citations
  4. 4Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma2023 · 55 citations
  5. 5Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE2021 · 150 citations